Therapeutic Solutions International, Inc.
TSOI · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.26 | -2.66 | 0.22 |
| FCF Yield | -33.81% | -6.71% | -1.49% | -5.43% |
| EV / EBITDA | -2.71 | -5.44 | -28.59 | -6.93 |
| Quality | ||||
| ROIC | -91.64% | -133.23% | -786.10% | 250.73% |
| Gross Margin | 62.86% | 61.58% | 70.85% | 79.59% |
| Cash Conversion Ratio | 0.49 | 0.28 | 0.24 | 0.30 |
| Growth | ||||
| Revenue 3-Year CAGR | -12.14% | 48.86% | 74.44% | 162.03% |
| Free Cash Flow Growth | -5.22% | -3.96% | -46.51% | -115.16% |
| Safety | ||||
| Net Debt / EBITDA | -0.58 | -0.35 | -0.43 | -0.42 |
| Interest Coverage | -4.69 | -5.08 | -3.77 | -6.11 |
| Efficiency | ||||
| Inventory Turnover | 1.63 | 1.87 | 1.07 | 2.37 |
| Cash Conversion Cycle | -3,724.40 | -1,640.36 | -3,081.42 | -8,668.17 |